Toll Free: 1-888-928-9744

Pulmonary Fibrosis - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 380 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pulmonary Fibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Pulmonary Fibrosis - Pipeline Review, H1 2016', provides an overview of the Pulmonary Fibrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Pulmonary Fibrosis Overview 11 Therapeutics Development 12 Pipeline Products for Pulmonary Fibrosis - Overview 12 Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 13 Pulmonary Fibrosis - Therapeutics under Development by Companies 14 Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 20 Pulmonary Fibrosis - Pipeline Products Glance 21 Clinical Stage Products 21 Early Stage Products 22 Pulmonary Fibrosis - Products under Development by Companies 23 Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 30 Pulmonary Fibrosis - Companies Involved in Therapeutics Development 31 AdAlta Pty Ltd. 31 Advinus Therapeutics Ltd. 32 Aeolus Pharmaceuticals, Inc. 33 Afferent Pharmaceuticals, Inc. 34 AnaMar AB 35 Angion Biomedica Corp. 36 Antitope Limited 37 aTyr Pharma, Inc. 38 Biogen, Inc. 39 Bioneer Corporation 40 BiOrion Technologies B.V. 41 Bristol-Myers Squibb Company 42 Carolus Therapeutics, Inc. 43 Celgene Corporation 44 Chong Kun Dang Pharmaceutical Corp. 45 Clanotech AB 46 Compugen Ltd. 47 Cynata Therapeutics Limited 48 Diffusion Pharmaceuticals Inc. 49 Digna Biotech, S.L. 50 Elsalys Biotech SAS 51 F. Hoffmann-La Roche Ltd. 52 FibroGen, Inc. 53 Galapagos NV 54 Galectin Therapeutics, Inc. 55 GenKyoTex S.A. 56 GlaxoSmithKline Plc 57 Global Blood Therapeutics, Inc. 58 HanAll Biopharma Co., Ltd. 59 HEC Pharm Co., Ltd. 60 Histocell S.L. 61 Hydra Biosciences, Inc. 62 iBio, Inc. 63 Inventiva 64 Isarna Therapeutics GmbH 65 Kadmon Corporation, LLC 66 Kasiak Research Private Limited 67 KineMed, Inc. 68 Kyorin Pharmaceutical Co., Ltd. 69 Lpath, Inc. 70 miRagen Therapeutics, Inc. 71 Moerae Matrix, Inc. 72 MorphoSys AG 73 NicOx S.A. 74 Novartis AG 75 Pacific Therapeutics Ltd. 76 Pharmaxis Limited 77 Pharmicell Co., Ltd. 78 Pluristem Therapeutics Inc. 79 Progenra, Inc. 80 Promedior, Inc. 81 ProMetic Life Sciences Inc. 82 Pulmatrix, Inc. 83 RedHill Biopharma Ltd. 84 Respira Therapeutics, Inc. 85 Rhizen Pharmaceuticals S.A. 86 Ribomic Inc. 87 Saje Pharma, LLC 88 Sanofi 89 SciFluor Life Sciences, LLC 90 Symic Biomedical, Inc. 91 TaiwanJ Pharmaceuticals Co., Ltd. 92 Teva Pharmaceutical Industries Limited 93 Therabron Therapeutics, Inc. 94 Vericel Corporation 95 Yuhan Corporation 96 Pulmonary Fibrosis - Therapeutics Assessment 97 Assessment by Monotherapy Products 97 Assessment by Combination Products 98 Assessment by Target 99 Assessment by Mechanism of Action 103 Assessment by Route of Administration 107 Assessment by Molecule Type 109 Drug Profiles 111 (acetylcysteine + pentoxifylline) - Drug Profile 111 ABC-294640 - Drug Profile 113 acALY-18 - Drug Profile 116 AEOL-10150 - Drug Profile 117 AF-219 - Drug Profile 121 Altepan - Drug Profile 123 AM-0010 - Drug Profile 124 AMAP-102 - Drug Profile 126 Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 128 Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile 129 BB-3 - Drug Profile 130 BG-00011 - Drug Profile 134 BMS-986020 - Drug Profile 135 BOT-191 - Drug Profile 136 CC-539 - Drug Profile 137 CC-90001 - Drug Profile 138 Cellgram-Lung - Drug Profile 139 CG-1011 - Drug Profile 140 CGEN-25009 - Drug Profile 141 CKD-942 - Drug Profile 142 CLT-28643 - Drug Profile 143 CM-101 - Drug Profile 144 CMYJH-01 - Drug Profile 145 CT-140 - Drug Profile 146 CT-2009 - Drug Profile 147 D-9030 - Drug Profile 148 DB-02901 - Drug Profile 149 disitertide - Drug Profile 150 Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 153 Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 154 FG-3019 - Drug Profile 155 GBT-1118 - Drug Profile 157 GBT-440 - Drug Profile 158 GKT-831 - Drug Profile 159 GLPG-1690 - Drug Profile 160 GRMD-02 - Drug Profile 161 GSK-3008348 - Drug Profile 164 HC-067047 - Drug Profile 165 HEC-00000585 - Drug Profile 166 HL-156FIB - Drug Profile 167 HR-017 - Drug Profile 168 IBIOCFB-03 - Drug Profile 169 ICG-001 - Drug Profile 171 iMod.Fc - Drug Profile 172 ISTH-0047 - Drug Profile 173 ITMN-10534 - Drug Profile 175 ITMN-14440 - Drug Profile 176 ITMN-30162 - Drug Profile 177 IVA-337 - Drug Profile 178 ixmyelocel-T - Drug Profile 179 JKB-117 - Drug Profile 182 JKB-119 - Drug Profile 183 KBP-7018 - Drug Profile 184 KD-025 - Drug Profile 185 lebrikizumab - Drug Profile 187 Lpathomab - Drug Profile 189 LT-0011 - Drug Profile 191 LTI-03 - Drug Profile 192 MGN-4220 - Drug Profile 193 MMI-0100 - Drug Profile 194 Monoclonal Antibodies to Inhibit S100-B for Idiopathic Pulmonary Fibrosis and COPD - Drug Profile 196 MOR-107 - Drug Profile 197 NAS-911 - Drug Profile 198 NCX-466 - Drug Profile 200 Neumomir - Drug Profile 201 noscapine - Drug Profile 202 Oligonucleotides for Respiratory and Oncology - Drug Profile 203 OLX-201 - Drug Profile 204 omipalisib - Drug Profile 205 P-007 - Drug Profile 207 P-013 - Drug Profile 208 PB-01 - Drug Profile 209 PBF-1129 - Drug Profile 211 PBI-4050 - Drug Profile 212 PBI-4425 - Drug Profile 214 Peptide to Target C/EBP-Beta for Lung Fibrosis - Drug Profile 215 pirfenidone - Drug Profile 216 PLX-PAD - Drug Profile 217 PNQ-103 - Drug Profile 221 PRI-724 - Drug Profile 222 PRM-151 - Drug Profile 224 PUR-1500 - Drug Profile 226 PXS-4820 - Drug Profile 227 Q-122 - Drug Profile 228 RBM-005 - Drug Profile 230 RBM-006 - Drug Profile 231 Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 232 Recombinant Peptides for Fibrosis - Drug Profile 233 Recombinant Protein for Inflammation and Pulmonary Fibrosis - Drug Profile 234 Refacell-IPF - Drug Profile 235 RES-529 - Drug Profile 236 RP-3128 - Drug Profile 239 RP-6503 - Drug Profile 240 RT-234 - Drug Profile 241 SAR-156597 - Drug Profile 242 SB-300 - Drug Profile 243 SD-560 - Drug Profile 244 SM-04646 - Drug Profile 245 Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile 246 Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 247 Small Molecule to Inhibit MAPK for Pulmonary Fibrosis - Drug Profile 248 Small Molecules for COPD and IPF - Drug Profile 249 Small Molecules for Fibrosis - Drug Profile 250 Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 251 Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 252 Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 253 Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile 254 Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 255 Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile 256 Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis - Drug Profile 257 Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile 258 Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 259 SPL-334 - Drug Profile 260 Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 261 Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile 262 Stem Cell Therapy for Lung Fibrosis - Drug Profile 263 Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 264 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 266 Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 268 TD-139 - Drug Profile 269 tipelukast - Drug Profile 271 TM-5441 - Drug Profile 273 vismodegib - Drug Profile 275 YH-siRNA1 - Drug Profile 279 ZL-2102 - Drug Profile 280 Pulmonary Fibrosis - Recent Pipeline Updates 281 Pulmonary Fibrosis - Dormant Projects 356 Pulmonary Fibrosis - Discontinued Products 362 Pulmonary Fibrosis - Product Development Milestones 363 Featured News & Press Releases 363 Appendix 370 Methodology 370 Coverage 370 Secondary Research 370 Primary Research 370 Expert Panel Validation 370 Contact Us 370 Disclaimer 371
List of Tables
Number of Products under Development for Pulmonary Fibrosis, H1 2016 21 Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Development by Companies, H1 2016 (Contd..1) 24 Number of Products under Development by Companies, H1 2016 (Contd..2) 25 Number of Products under Development by Companies, H1 2016 (Contd..3) 26 Number of Products under Development by Companies, H1 2016 (Contd..4) 27 Number of Products under Development by Companies, H1 2016 (Contd..5) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Development, H1 2016 31 Products under Development by Companies, H1 2016 32 Products under Development by Companies, H1 2016 (Contd..1) 33 Products under Development by Companies, H1 2016 (Contd..2) 34 Products under Development by Companies, H1 2016 (Contd..3) 35 Products under Development by Companies, H1 2016 (Contd..4) 36 Products under Development by Companies, H1 2016 (Contd..5) 37 Products under Development by Companies, H1 2016 (Contd..6) 38 Products under Investigation by Universities/Institutes, H1 2016 39 Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2016 40 Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2016 41 Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 42 Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 43 Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2016 44 Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016 45 Pulmonary Fibrosis - Pipeline by Antitope Limited, H1 2016 46 Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H1 2016 47 Pulmonary Fibrosis - Pipeline by Biogen, Inc., H1 2016 48 Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H1 2016 49 Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016 50 Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 51 Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016 52 Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2016 53 Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 54 Pulmonary Fibrosis - Pipeline by Clanotech AB, H1 2016 55 Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2016 56 Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H1 2016 57 Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 58 Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2016 59 Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H1 2016 60 Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 61 Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2016 62 Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2016 63 Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 64 Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2016 65 Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016 66 Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H1 2016 67 Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 68 Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016 69 Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2016 70 Pulmonary Fibrosis - Pipeline by Hydra Biosciences, Inc., H1 2016 71 Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2016 72 Pulmonary Fibrosis - Pipeline by Inventiva, H1 2016 73 Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016 74 Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H1 2016 75 Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H1 2016 76 Pulmonary Fibrosis - Pipeline by KineMed, Inc., H1 2016 77 Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 78 Pulmonary Fibrosis - Pipeline by Lpath, Inc., H1 2016 79 Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2016 80 Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2016 81 Pulmonary Fibrosis - Pipeline by MorphoSys AG, H1 2016 82 Pulmonary Fibrosis - Pipeline by NicOx S.A., H1 2016 83 Pulmonary Fibrosis - Pipeline by Novartis AG, H1 2016 84 Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2016 85 Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2016 86 Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H1 2016 87 Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H1 2016 88 Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2016 89 Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2016 90 Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016 91 Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2016 92 Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H1 2016 93 Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H1 2016 94 Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 95 Pulmonary Fibrosis - Pipeline by Ribomic Inc., H1 2016 96 Pulmonary Fibrosis - Pipeline by Saje Pharma, LLC, H1 2016 97 Pulmonary Fibrosis - Pipeline by Sanofi, H1 2016 98 Pulmonary Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016 99 Pulmonary Fibrosis - Pipeline by Symic Biomedical, Inc., H1 2016 100 Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 101 Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 102 Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H1 2016 103 Pulmonary Fibrosis - Pipeline by Vericel Corporation, H1 2016 104 Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H1 2016 105 Assessment by Monotherapy Products, H1 2016 106 Assessment by Combination Products, H1 2016 107 Number of Products by Stage and Target, H1 2016 109 Number of Products by Stage and Mechanism of Action, H1 2016 113 Number of Products by Stage and Route of Administration, H1 2016 117 Number of Products by Stage and Molecule Type, H1 2016 119 Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016 290 Pulmonary Fibrosis - Dormant Projects, H1 2016 365 Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2016 366 Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2016 367 Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2016 368 Pulmonary Fibrosis - Dormant Projects (Contd..4), H1 2016 369 Pulmonary Fibrosis - Dormant Projects (Contd..5), H1 2016 370 Pulmonary Fibrosis - Discontinued Products, H1 2016 371


List of Figures
Number of Products under Development for Pulmonary Fibrosis, H1 2016 21 Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 23 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Clinical Stage Development, H1 2016 30 Comparative Analysis by Early Stage Products, H1 2016 31 Assessment by Monotherapy Products, H1 2016 106 Number of Products by Top 10 Targets, H1 2016 108 Number of Products by Stage and Top 10 Targets, H1 2016 108 Number of Products by Top 10 Mechanism of Actions, H1 2016 112 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 112 Number of Products by Top 10 Routes of Administration, H1 2016 116 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 116 Number of Products by Top 10 Molecule Types, H1 2016 118 Number of Products by Stage and Top 10 Molecule Types, H1 2016 118

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify